Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) just announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date. Mino-Lok: Citius recently announced positive topline data from the Phase 3 study of Mino-Lok® in catheterrelated bloodstream infections (CRBSIs). Primary and secondary endpoints were met with statistical significance. In addition to the initial indication, two investigator-initiated Phase 1 studies of LYMPHIR are underway to explore how the differenti ...

CRANFORD, N.J., July 10, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date Citius significantly advanced its two late-stage product candidates in the first six months of 2024, and expects several key milestones in the nea ...

Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first- in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates: Mino-Lok® and LYMPHIR™. In May 2024, Citius announced positive topline results of Mino-Lok, its antibiotic lock solution to salvage catheters in patients with bloodstream infections. The Biologics License Application for LYMP ...

Citius Pharmaceuticals (NASDAQ:CTXR) stock is on the rise Tuesday after the company announced new results from its Phase 3 clinical trial of Mino-Lok.Mino-Lok is Citius Pharmaceuticals’ antibiotic lock solution for patients with central line-associated infections or catheter-related bloodstream infections. The good news for CTXR investors is that this trail met both its primary and secondary endpoints.The primary endpoint was extending the time until catheter failure. In the control arm, the median failure ...

Trial achieves statistically significant primary endpoint (p=0.0006) Secondary endpoint demonstrates statistically significant overall success of Mino-Lok therapy with a greater percentage of patients retaining their catheters (p=0.0025) CRANFORD, N.J., May 21, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced positive ...

Citius Pharma (NASDAQ:CTXR) just reported results for the second quarter of 2024.Citius Pharma reported earnings per share of -5 cents. This met the analyst estimate for EPS of -5 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. Th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from ______________ to ______________ Citius Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) incorporation or organization) Identification No.) 11 Commerce Drive, First Floor, Cranford, NJ 07016 (Address of principal executive of ices) (Zip Code) Securities registered pu ...

CRANFORD, N.J., May 10, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences. Citius Chairman and CEO Leonard Mazur will host one-on-one investor meetings at the EF Hutton Annual Global Conference on May 15, 2024, and present and host one-on-one investor meetings at t ...

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase up to an aggregate of 21,428,574 shares of its common stock, at a purchase price of $0 ...

National Cancer Institute (NCI)-designated research and treatment center City of Hope, in Duarte, CA, to participate in the University of Minnesota (UMN) Masonic Cancer Center's ongoing Phase 1 trial to determine the maximum tolerated dose of LYMPHIR plus CAR-T therapy CRANFORD, N.J., April 11, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announc ...